Article
Gastroenterology & Hepatology
Kumar Krishnan, Manoop S. Bhutani, Harry R. Aslanian, Joshua Melson, Udayakumar Navaneethan, Rahul Pannala, Mansour A. Parsi, Allison R. Schulman, Amrita Sethi, Shelby Sullivan, Guru Trikudanathan, Arvind J. Trindade, Rabindra R. Watson, John T. Maple, David R. Lichtenstein
Summary: The study reviewed technologies and methods for enhanced imaging during EUS, focusing on elastography and contrast-enhanced EUS. These technologies are valuable for evaluating pancreatic mass lesions and providing adjunctive diagnostic information in specific clinical situations.
GASTROINTESTINAL ENDOSCOPY
(2021)
Article
Oncology
Anliu Tang, Li Tian, Kui Gao, Rui Liu, Shan Hu, Jinzhu Liu, Jiahao Xu, Tian Fu, Zinan Zhang, Wujun Wang, Long Zeng, Weiming Qu, Yong Dai, Ruirui Hou, Shoujiang Tang, Xiaoyan Wang
Summary: The study aimed to develop a deep learning-based artificial intelligence system, CH-EUS MASTER, for diagnosing pancreatic masses and guiding real-time EUS-FNA. The results showed that CH-EUS MASTER significantly improved the accuracy of diagnosing pancreatic masses and increased the first-pass diagnostic yield in EUS-FNA.
Article
Gastroenterology & Hepatology
Kosuke Minaga, Masayuki Kitano, Atsushi Nakai, Shunsuke Omoto, Ken Kamata, Kentaro Yamao, Mamoru Takenaka, Masakatsu Tsurusaki, Takaaki Chikugo, Ippei Matsumoto, Yasutaka Chiba, Tomohiro Watanabe, Masatoshi Kudo
Summary: CH-EUS-based Kupffer-phase imaging improves the detection rate of left liver lobe metastasis from pancreatic cancer and plays a crucial role in clinical decision-making. Its sensitivity for detecting small liver metastasis is significantly higher than CE-CT or FB-EUS.
GASTROINTESTINAL ENDOSCOPY
(2021)
Review
Cardiac & Cardiovascular Systems
Russell Franks, Sven Plein, Amedeo Chiribiri
Summary: Dynamic contrast enhanced CMR perfusion imaging is a reliable non-invasive tool for the evaluation and risk stratification of patients with coronary artery disease. It offers high spatial and temporal resolution, and does not involve ionizing radiation, making it recommended by international guidelines.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Marianna E. Horn, Markus Brinkmann, Steven Machtaler
Summary: The intestine is crucial for nutrient uptake and as a defense against pathogens. Inflammation in the intestine can have serious health consequences, and traditional detection methods are invasive. Contrast-enhanced ultrasound (CEUS) imaging presents a non-invasive and cost-effective way to measure inflammation in patients. The use of CEUS has been demonstrated in quantifying vascular perfusion in rainbow trout intestines, showing a potential for broader application in industry and research.
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY
(2023)
Article
Multidisciplinary Sciences
Chuan Chen, Reshani Perera, Michael C. Kolios, Hessel Wijkstra, Agata A. Exner, Massimo Mischi, Simona Turco
Summary: Investigation of a unique second-wave phenomenon in nanobubble contrast-enhanced ultrasound (CEUS) imaging was conducted. The second wave was observed accompanying the first pass of the contrast agent bolus, which has not been previously observed in CEUS with microbubbles. The study aimed to investigate this phenomenon and its potential clinical applications, and found that the characteristics of the second wave differed between tumor and normal tissue, suggesting its potential for cancer diagnosis.
SCIENTIFIC REPORTS
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yanjie Wang, Guanghan Li, Kun Yan, Zhihui Fan, Rong Long, Jun Shan, Ying Dai, Wei Wu
Summary: The study explored the diagnostic value of six CEUS enhancement patterns for solid pancreatic lesions and found good concordance between observers. The diagnostic accuracy of CEUS was significantly different from that of US, but not significantly different from that of enhanced CT. The different enhancement patterns on CEUS were clinically valuable for differentiation of solid pancreatic lesions.
EUROPEAN RADIOLOGY
(2022)
Article
Environmental Sciences
Una Goncin, Ngoc Ton, Ashwin Reddy, Ahmed El Kaffas, Markus Brinkmann, Steven Machtaler
Summary: This study demonstrates the potential of contrast-enhanced ultrasound (CEUS) imaging for measuring organ blood flow in fish, visualizing contrast enhancement in the liver of rainbow trout, and detecting the effects of drugs on blood flow. CEUS shows promise for exploring different organs, fish species, and the impact of chemical contaminants in future research.
SCIENCE OF THE TOTAL ENVIRONMENT
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Nan Huang, Yu Chen, Dejun She, Zhen Xing, Tanhui Chen, Dairong Cao
Summary: The combined use of DKI and DCE-MRI can help differentiate different types of parotid gland tumors, improving diagnostic accuracy.
EUROPEAN RADIOLOGY
(2022)
Review
Gastroenterology & Hepatology
Andrea Lisotti, Bertrand Napoleon, Antonio Facciorusso, Anna Cominardi, Stefano Francesco Crino, Nicole Brighi, Rodica Gincul, Masayuki Kitano, Yasunobu Yamashita, Giovanni Marchegiani, Pietro Fusaroli
Summary: The study provided robust evidence on the value of CE-EUS for the characterization of mural nodules within PCNs. CH-EUS offered an increased diagnostic yield in the identification and characterization of malignant mural nodules.
GASTROINTESTINAL ENDOSCOPY
(2021)
Article
Acoustics
Keren T. Karlinsky, Tali Ilovitsh
Summary: This article presents an enhanced real-time nonlinear imaging technique based on the excitation of microbubbles (MBs) with a dual frequency waveform. By triggering a frequency mixing effect, the technique amplifies the MB's nonlinear response and enhances image contrast.
IEEE TRANSACTIONS ON ULTRASONICS FERROELECTRICS AND FREQUENCY CONTROL
(2022)
Article
Cell Biology
Li He, Ze Li, Qunzi Zhang, Yini Chen, Yihui Gao, Teng Chen, Niansong Wang, Lixin Jiang, Ying Fan
Summary: This study investigated the use of contrast-enhanced ultrasound (CEUS) as a diagnostic tool for hyperuricemic nephropathy (HN). The results showed that CEUS could detect abnormal renal perfusion in HN rats and early stage chronic kidney disease patients with HN, which correlated with renal function decline.
DISEASE MODELS & MECHANISMS
(2022)
Review
Medicine, General & Internal
Tommaso Vincenzo Bartolotta, Angelo Randazzo, Eleonora Bruno, Pierpaolo Alongi, Adele Taibbi
Summary: The introduction of CEUS has significantly improved the diagnostic accuracy of ultrasound in characterizing pancreatic masses by providing dynamic information using a blood pool contrast agent without ionizing radiation. This article summarizes the CEUS imaging findings of various solid and cystic pancreatic lesions based on personal experience and literature data.
Review
Hematology
Isabel Wiesinger, Friedrich Jung, Ernst Michael Jung
Summary: This review summarizes the use of external perfusion software for contrast-enhanced ultrasound in various tissues, introducing useful perfusion parameters for characterization and detection of micro-vascularization within non-cystic lesions.
CLINICAL HEMORHEOLOGY AND MICROCIRCULATION
(2021)
Article
Gastroenterology & Hepatology
In Rae Cho, Seok-Hoo Jeong, Huapyong Kang, Eui Joo Kim, Yeon Suk Kim, Jae Hee Cho
Summary: The study found that there was no significant difference in diagnostic sensitivity for solid pancreatic lesions between CEH-EUS and conventional EUS. CEH-EUS-guided FNA/FNB sampling may not need to be routinely used and can be selectively considered for small, indeterminate lesions.
GASTROINTESTINAL ENDOSCOPY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Naoshi Nishida, Masatoshi Kudo
Summary: With the development of advanced methods for diagnosis and treatment, the complexity of medical data has increased, leading to the potential for misinterpretation and serious consequences. Artificial intelligence (AI) can help avoid human errors and has shown promising results in diagnosing and managing liver diseases. This paper summarizes recent advances in AI for liver disease and introduces the use of AI in diagnosing liver tumors using B-mode ultrasonography.
Article
Oncology
Andrea Casadei-Gardini, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, Jose Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Margarida Montes, Caterina Vivaldi, Caterina Solda, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mara Persano, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Stefano Cascinu, Alessandro Cucchetti
Summary: This retrospective multi-center study compared the clinical efficacy and safety of lenvatinib and atezolizumab plus bevacizumab as a first-line treatment for unresectable HCC. The results showed that atezolizumab plus bevacizumab did not have a significant survival advantage over lenvatinib overall. However, lenvatinib had a higher overall survival rate in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease, while atezolizumab plus bevacizumab had a higher overall survival rate in patients with viral hepatitis. After adjusting for population, atezolizumab plus bevacizumab provided better safety profile for most adverse events.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Gastroenterology & Hepatology
Naoya Kato, Masatoshi Kudo, Kaoru Tsuchiya, Atsushi Hagihara, Kazushi Numata, Hiroshi Aikata, Yoshitaka Inaba, Shunsuke Kondo, Kenta Motomura, Naohiro Okano, Masafumi Ikeda, Manabu Morimoto, Shingo Kuroda, Akiko Kimura
Summary: Cabozantinib demonstrated efficacy and manageable safety profile in Japanese patients with advanced HCC. The median PFS was 7.4 months in the prior-sorafenib cohort and 3.6 months in the sorafenib-naive cohort. Disease control rate was 85.0% and 64.3% in the prior-sorafenib and sorafenib-naive cohorts, respectively. The most common adverse events were palmar-plantar erythrodysesthesia syndrome, diarrhea, hypertension, and decreased appetite. No new safety concerns were identified.
HEPATOLOGY RESEARCH
(2023)
Article
Gastroenterology & Hepatology
Dominique Thabut, Masatoshi Kudo
Summary: Portal hypertension and hepatocellular carcinoma commonly coexist and their association affects the prognosis of cirrhosis patients. The interplay between these conditions has therapeutic significance in terms of treating HCC and managing PHT complications. The management recommendations for PHT have been revised, with new screening and prophylaxis indications. PHT may limit locoregional therapies and TIPS placement can be considered for HCC patients. New systemic HCC therapies can impact PHT levels and increase the risk of bleeding. Prevention and adequate treatment of PHT complications are important, particularly in advanced HCC cases. This expert opinion discusses specific aspects of managing both conditions, incorporating recent data in the HCC field.
JOURNAL OF HEPATOLOGY
(2023)
Article
Oncology
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Jose Presa Ramos, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Bernardo Stefanini, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Margarida Montes, Caterina Vivaldi, Caterina Solda, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Summary: This real-world study investigates the association between the prognostic nutritional index (PNI) and clinical outcomes in HCC patients treated with atezolizumab plus bevacizumab. The study shows that high PNI is associated with longer overall survival and progression-free survival.
Article
Oncology
Masatoshi Kudo, Richard S. S. Finn, Peter R. R. Galle, Andrew X. X. Zhu, Michel Ducreux, Ann-Lii Cheng, Masafumi Ikeda, Kaoru Tsuchiya, Ken-ichi Aoki, Jing Jia, Riccardo Lencioni
Summary: The study demonstrates the efficacy and safety of atezolizumab + bevacizumab treatment in patients with baseline BCLC Stage B hepatocellular carcinoma, consistent with the overall study population.
Article
Oncology
Masatoshi Kudo, Richard S. Finn, Ann-Lii Cheng, Andrew X. Zhu, Michel Ducreux, Peter R. Galle, Naoya Sakamoto, Naoya Kato, Michitaka Nakano, Jing Jia, Arndt Vogel
Summary: This exploratory analysis examined the prognostic impact of baseline albumin-bilirubin (ALBI) score in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab + bevacizumab or sorafenib. The study found that atezolizumab + bevacizumab improved overall survival and progression-free survival compared to sorafenib in patients with ALBI score of 1, but not in patients with ALBI score of 2. ALBI grade appeared to be prognostic for outcomes in both treatment groups.
Article
Oncology
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stephane Cattan, Yee Chao, Abby B. Siegel, Ivan Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn
Summary: With extended follow-up, pembrolizumab demonstrated continued improvement in overall survival (OS) and progression-free survival (PFS) compared to placebo in advanced hepatocellular carcinoma (HCC) patients previously treated with sorafenib. The adverse event profile of pembrolizumab remained consistent with placebo.
Article
Oncology
Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, Kaoru Tsuchiya, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Naoshi Nishida, Chikara Ogawa, Tetsu Tomonari, Noriaki Nakamura, Hidekatsu Kuroda, Atsushi Takebe, Yoshifumi Takeyama, Masaaki Hidaka, Susumu Eguchi, Stephen L. Chan, Masayuki Kurosaki, Namiki Izumi
Summary: The concept of curative conversion by combining systemic therapy and locoregional therapy in intermediate-stage HCC has not been reported before. This study aimed to show the value of curative conversion in immunotherapy-treated HCC. The results showed that 35% of patients achieved CR through resection, ablation, or super selective TACE.
Review
Oncology
Satoru Hagiwara, Naoshi Nishida, Masatoshi Kudo
Summary: Immunotherapy for hepatocellular carcinoma (HCC) is rapidly advancing, with a focus on analyzing the tumor immune environment and developing custom-made treatments. Understanding the immune environment of HCC is vital for selecting appropriate immune checkpoint inhibitors (ICIs) and managing their side effects. This summary aims to review the progress of immunotherapy in HCC and its implications for future treatment.
Article
Oncology
Naoshi Nishida, Tomoko Aoki, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Hiroshi Ida, Satoru Hagiwara, Yasunori Minami, Kazuomi Ueshima, Masatoshi Kudo
Summary: Cholangiocarcinoma (CCA) is a resistant cancer, and a majority of CCAs have a non-inflamed tumor phenotype resistant to treatment, including immune checkpoint inhibitors (ICIs). This study aimed to understand the molecular characteristics of non-inflamed CCAs. The genetic/epigenetic status of 36 CCAs was analyzed, and it was found that tumors with alterations in FGFR2 and IDH1/2 had a non-inflamed phenotype. Downregulation of genes involved in antigen presentation and DNA methylation were associated with the non-inflamed phenotype. These findings provide important insights for developing new strategies to treat CCA.
Review
Medicine, General & Internal
Yasuo Otsuka, Ken Kamata, Masatoshi Kudo
Summary: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is a useful method for diagnosing pancreatic masses. The diagnostic performance of EUS-FNA can be improved by using contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS), which helps avoid fibrosis in the pancreatic mass. However, the effectiveness of CH-EUS-FNA is still a matter of debate, as only one out of eight studies showed improved sensitivity.
Article
Medicine, General & Internal
Yasuo Otsuka, Yoriaki Komeda, Masayuki Takeda, Takayuki Takahama, Masashi Kono, Mamoru Takenaka, Satoru Hagiwara, Naoshi Nishida, Hiroshi Kashida, Masatoshi Kudo
Summary: A 76-year-old woman presented with lower abdominal pain and nausea. Imaging showed a soft tissue mass extending to the liver surface, diagnosed as epithelioid mesothelioma. After chemotherapy, the patient achieved long-term survival of more than 5 years.
CASE REPORTS IN MEDICINE
(2023)
Review
Oncology
Yasunori Minami, Tomoko Aoki, Satoru Hagiwara, Masatoshi Kudo
Summary: Thermal ablation therapy, including RFA and MWA, is a widely used treatment for hepatocellular carcinomas. It achieves good outcomes with minimal invasiveness. Successful thermal ablation therapy requires understanding the principles and characteristics of the treatment, assessing the benefits and risks, precise needle control and visualization, utilizing imaging guidance techniques, and evaluating therapeutic response. This overview provides essential information for the clinical application of thermal ablation.
Article
Oncology
Masatoshi Kudo
